GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentThe China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback